FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111915523> ?p ?o ?g. }

• W2111915523 endingPage "628" @default.
• W2111915523 startingPage "620" @default.
• W2111915523 abstract "J. Scott Nystrom 1 , John C. Hornberger 2,3 , Gauri R. Varadhachary 4 , Richard J. Hornberger 3 , Hialy R. Gutierrez 3 , W. David Henner 5 , Shawn H. Becker 5 , Mahul B. Amin 6 , and Michael G. Walker 2 1 Department of Medicine, Tufts Medical Center, Boston, MA, USA 2 Department of Medicine, Stanford University, Stanford, CA, USA 3 Cedar Associates LLC, Menlo Park, CA, USA 4 Department of Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA 5 Pathwork Diagnostics, Inc., Redwood City, CA, USA 6 Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA Received: May 22, 2012; Accepted: June 08, 2012; Published: June 9, 2012; Keywords: cancer of unknown primary, diagnosis, genomics, clinical utility, tissue of origin Correspondence: John Hornberger, email: // // Abstract PURPOSE: The primary tissue-site origin in over 4% of cancers remains uncertain despite thorough clinicopathological evaluation. This study assessed the effect of a Food and Drug Administration-cleared 2,000-gene–expression-profiling (GEP) test on primary tissue-site working diagnoses and management for metastatic and poorly differentiated cancers. METHODS: Clinical information was collected from physicians ordering the GEP test for patients with difficult to diagnose cancers. Endpoints included diagnostic procedures, physicians’ working diagnoses and treatment recommendations before and after GEP result availability, and physician reports of the test’s usefulness for clinical decision making. Patient date of death was obtained, with a minimum of one year follow-up from date of biopsy. RESULTS: Sixty-five physicians participated in the study (n=107 patients). Before GEP, patients underwent 3.2 investigations on average (e.g., radiology, endoscopy). Ten immunohistochemistry tests were used per biopsy (SD 5.2). After GEP testing, physicians changed the primary working diagnosis for 50% of patients (95% CI: 43%,58%) and management for 65% of patients (95% CI: 58%,73%). With GEP results, the recommendation for guideline-consistent chemotherapy increased from 42% to 65% of patients, and the recommendation for non-guideline-consistent regimens declined from 28% to 13%. At last follow-up, 69 patients had died, and median survival was 14.0 months (95% CI: 10.2,18.6). Thirty-three percent of patients were alive at 2 years. CONCLUSION: In patients with difficult-to-diagnose cancers, GEP changed the working diagnosis and management for the majority of patients. Patients for whom the GEP test was ordered had longer median survival than that historically reported for patients enrolled in treatment trials for cancer of unknown primary." @default.
• W2111915523 created "2016-06-24" @default.
• W2111915523 creator A5001854589 @default.
• W2111915523 creator A5006472329 @default.
• W2111915523 creator A5020975270 @default.
• W2111915523 creator A5025092634 @default.
• W2111915523 creator A5027462202 @default.
• W2111915523 creator A5032611117 @default.
• W2111915523 creator A5043709533 @default.
• W2111915523 creator A5080708088 @default.
• W2111915523 creator A5088853428 @default.
• W2111915523 date "2012-06-09" @default.
• W2111915523 modified "2023-10-18" @default.
• W2111915523 title "Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival" @default.
• W2111915523 cites W1956998217 @default.
• W2111915523 cites W1970488378 @default.
• W2111915523 cites W1972615495 @default.
• W2111915523 cites W1978470415 @default.
• W2111915523 cites W1979744230 @default.
• W2111915523 cites W1984477277 @default.
• W2111915523 cites W1997274616 @default.
• W2111915523 cites W2001430684 @default.
• W2111915523 cites W2055164947 @default.
• W2111915523 cites W2058087313 @default.
• W2111915523 cites W2093151393 @default.
• W2111915523 cites W2141670106 @default.
• W2111915523 cites W2142346996 @default.
• W2111915523 cites W2142374454 @default.
• W2111915523 cites W2146272590 @default.
• W2111915523 cites W2156793788 @default.
• W2111915523 cites W2158734599 @default.
• W2111915523 cites W2513910737 @default.
• W2111915523 cites W2616257794 @default.
• W2111915523 cites W4251623465 @default.
• W2111915523 doi "https://doi.org/10.18632/oncotarget.521" @default.
• W2111915523 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3442294" @default.
• W2111915523 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22689213" @default.
• W2111915523 hasPublicationYear "2012" @default.
• W2111915523 type Work @default.
• W2111915523 sameAs 2111915523 @default.
• W2111915523 citedByCount "16" @default.
• W2111915523 countsByYear W21119155232012 @default.
• W2111915523 countsByYear W21119155232013 @default.
• W2111915523 countsByYear W21119155232014 @default.
• W2111915523 countsByYear W21119155232016 @default.
• W2111915523 countsByYear W21119155232018 @default.
• W2111915523 countsByYear W21119155232019 @default.
• W2111915523 countsByYear W21119155232021 @default.
• W2111915523 crossrefType "journal-article" @default.
• W2111915523 hasAuthorship W2111915523A5001854589 @default.
• W2111915523 hasAuthorship W2111915523A5006472329 @default.
• W2111915523 hasAuthorship W2111915523A5020975270 @default.
• W2111915523 hasAuthorship W2111915523A5025092634 @default.
• W2111915523 hasAuthorship W2111915523A5027462202 @default.
• W2111915523 hasAuthorship W2111915523A5032611117 @default.
• W2111915523 hasAuthorship W2111915523A5043709533 @default.
• W2111915523 hasAuthorship W2111915523A5080708088 @default.
• W2111915523 hasAuthorship W2111915523A5088853428 @default.
• W2111915523 hasBestOaLocation W21119155231 @default.
• W2111915523 hasConcept C121608353 @default.
• W2111915523 hasConcept C126322002 @default.
• W2111915523 hasConcept C142724271 @default.
• W2111915523 hasConcept C143998085 @default.
• W2111915523 hasConcept C534262118 @default.
• W2111915523 hasConcept C71924100 @default.
• W2111915523 hasConceptScore W2111915523C121608353 @default.
• W2111915523 hasConceptScore W2111915523C126322002 @default.
• W2111915523 hasConceptScore W2111915523C142724271 @default.
• W2111915523 hasConceptScore W2111915523C143998085 @default.
• W2111915523 hasConceptScore W2111915523C534262118 @default.
• W2111915523 hasConceptScore W2111915523C71924100 @default.
• W2111915523 hasIssue "6" @default.
• W2111915523 hasLocation W21119155231 @default.
• W2111915523 hasLocation W21119155232 @default.
• W2111915523 hasLocation W21119155233 @default.
• W2111915523 hasLocation W21119155234 @default.
• W2111915523 hasOpenAccess W2111915523 @default.
• W2111915523 hasPrimaryLocation W21119155231 @default.
• W2111915523 hasRelatedWork W1995515455 @default.
• W2111915523 hasRelatedWork W2080531066 @default.
• W2111915523 hasRelatedWork W2224319365 @default.
• W2111915523 hasRelatedWork W2748952813 @default.
• W2111915523 hasRelatedWork W2886693089 @default.
• W2111915523 hasRelatedWork W2899084033 @default.
• W2111915523 hasRelatedWork W2989971117 @default.
• W2111915523 hasRelatedWork W3031052312 @default.
• W2111915523 hasRelatedWork W3032375762 @default.
• W2111915523 hasRelatedWork W3108674512 @default.
• W2111915523 hasVolume "3" @default.
• W2111915523 isParatext "false" @default.
• W2111915523 isRetracted "false" @default.
• W2111915523 magId "2111915523" @default.
• W2111915523 workType "article" @default.